Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, today announces the availability of its new fully synthetic, human Fab fragment library.
An announcement will be made at the 13th annual PEGS meeting in Boston, MA by Guy Hermans, Isogenica’s CSO, who commented: “This novel fully synthetic antibody library, built using the company’s DNA library synthesis method (COLIBRA™), takes advantage of the most up to date understanding of the human antibody repertoire. Combining massive sequence diversity and dispersity with high functionality and developability, it offers the most efficient route to therapeutic antibody lead identification. We provide this library in the industry standard phagemid display format to allow for immediate integration in our licensees’ existing workflows”.
Adam Collier, Isogenica’s Director of Commercial Development, said: “This is a very significant opportunity for Isogenica and its licensees. Fully synthetic antibody libraries offer significant advantages over ...
